



Menopause misinformation is harming care

Symptoms should be prioritised ahead of testing

Marie K Christakis,^{1, 2} Taylor Roebbotham,^{1, 2} Stephanie Sterry,³ Olexandra Koshkina⁴

¹ Department of Obstetrics and Gynaecology, Temerty Faculty of Medicine University of Toronto, Toronto, Canada

² Weston and O'Brien Centre for Mature Women's Health, Sinai Health, Toronto, Ontario, Canada

³ Suffolk, UK

⁴ Division of Endocrinology and Metabolism, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

Correspondence to: M Christakis
Marie.Christakis@sinaihealth.ca

Cite this as: *BMJ* 2025;390:r1695

<http://doi.org/10.1136/bmj.r1695>

Published: 20 August 2025

A societal transformation of attitudes and beliefs surrounding menopausal hormone therapy (MHT) has outpaced provider education, leaving primary care specialties unprepared to deliver this care.¹ In the UK, MHT is more commonly referred to as hormone replacement therapy (HRT). Internationally, however, the term MHT is increasingly preferred because it more accurately reflects the full range of treatments used to manage symptoms and health effects of menopause, emphasising the importance of individualised care.²

A cultural shift has arisen owing to several converging factors: an increased awareness of the potential benefits of MHT,³ a better understanding of the risk profile of MHT,⁴ and a destigmatisation of menopause through press, social media, and celebrity coverage.⁵ As women are increasingly empowered to seek relief for menopausal symptoms, there has been a sharp rise in services that aim to address this growing demand. Although no global quantitative data are available regarding the increased uptake of these services, a recent Canadian report of aggregate health insurance claims indicates that the use of MHT in women aged 45 to 65 increased by 21% from 2020 to 2023.⁶ Further, studies in Sweden,⁷ Wales,⁸ and England⁹ demonstrate a substantial rise in the prescribing of MHT—up to 50% over recent years. Digital health technologies that are available direct to consumer (such as mobile applications, telehealth clinics, podcasts, and websites) have targeted menopause management, raising concerns about the reliability and potential commercial bias of the information.^{10 11} A decade ago, the global “femtech” market was valued at \$500m (£375m; €430m); today, it is estimated at \$28bn and is continuing to grow.¹² One of the most troubling trends arising from this surge is the promotion of routine hormone panel testing for the evaluation of menopausal symptoms—often including serum, salivary, or urine assays for oestradiol, progesterone, testosterone, dehydroepiandrosterone, thyroid hormones, and even cortisol. These tests can cost hundreds of dollars and are marketed to patients and clinicians as necessary for “individualising” hormone therapy.^{13 14} Many women who access this type of testing are unaware of the limited supporting evidence and are influenced by trust in their healthcare provider.¹⁵ In reality, these tests are of limited clinical use because there is no clearly defined therapeutic window for MHT, and some testing techniques do not offer accurate or precise assessment of hormone levels.¹⁶

Beyond questions of clinical validity, the utility of hormone testing is constrained by the physiology of the menopause transition. Perimenopause is characterised by highly variable day to day fluctuations in oestradiol and follicle stimulating

hormone levels that contribute to vasomotor symptoms, sleep disturbance, mood changes, and cognitive concerns. Observance of “normal” hormone levels can lead to underdiagnosis and undertreatment of women with symptoms. Postmenopause is defined by a predictable drop in oestradiol and rise in follicle stimulating hormone; however, there is no definitive test to differentiate this from perimenopause. The principle of evidence based practice is that a test should only be done if the result will directly guide patient care. For perimenopause and menopause, hormone testing offers no reliable way to determine who will benefit from treatment, when the final menstrual period will occur, or whether it is safe to discontinue contraception. Clinical guidelines from the British Menopause Society, National Institute for Health and Care Excellence, American College of Obstetricians and Gynecologists, The Menopause Society, and Endocrine Society agree: in women over age 45 presenting with validated symptoms of menopause, including menstrual irregularity, menopause is a clinical diagnosis, and hormone testing is unnecessary.^{17–21}

Despite this, many women now present with detailed hormone panels from wellness providers or online services. When this testing is used to make treatment decisions, it can mislead women into believing they are not candidates for MHT or prompt the use of unsupported interventions.²² In our experience, these panels are often used to justify taking compounded hormone regimens or supplements based on marginal deviations from hormone thresholds that are not grounded in evidence.^{16 23} Compounded bioidentical hormone therapy lacks standardisation and regulatory oversight and has not been tested for safety or efficacy.²³ There is concern that inconsistencies in the quantities of oestrogen or progesterone in compounded bioidentical hormone therapy regimens can result in endometrial hyperplasia or carcinoma, particularly in women with an intact uterus who are receiving inadequate progesterone.²⁴

Symptom driven approach needed

There is a growing recognition that menopause care is most effective when grounded in an approach that is symptom driven and patient centred. Vasomotor symptoms, insomnia, mood changes, and vaginal dryness are best assessed by a thorough clinical history rather than by hormone levels. For women under 60 or within 10 years of menopause onset, MHT is the most effective treatment for vasomotor and genitourinary symptoms, with a favourable safety profile in appropriately selected patients.²⁵ While hormone panel testing and associated misinformation can muddy the waters of clinical decision making,

we maintain that treatment decisions should be guided by clinical response and patient preferences.

Routine hormone panel testing in the management of menopause symptoms is not supported by current evidence and does not improve care—whether before starting MHT, or to titrate dosing.²⁶ Until we can establish individualised target hormone levels by accounting for pharmacokinetics, receptor specific pharmacodynamics, and differentiating between endogenous and exogenous hormones, there is no role for commercial hormonal panel testing to guide therapy. In the meantime, such testing offers only a false sense of precision. Although innovation is needed, the normalisation of hormone panel testing could be a symptom of a larger problem: the commercialisation of women's health and a movement away from evidence based practice. For midlife women, effective treatment begins not with numbers, but with listening.

Competing interest: None declared.

Provenance and peer review: Commissioned; externally peer reviewed.

- 1 Kling JM, MacLaughlin KL, Schnatz PF, et al. Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents: a cross-sectional survey. *Mayo Clin Proc* 2019;94:-53. doi: 10.1016/j.mayocp.2018.08.033. pmid: 30711122
- 2 Panay N, Ang SB, Cheshire R, et al. Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper. *Climacteric* 2024;27:-57. doi: 10.1080/13697137.2024.2394950
- 3 Pershad A, Morris JM, Shearer K, Pace D, Khanna P. Influencing factors on women's attitudes toward hormone therapy acceptance for menopause treatment: a systematic review. *Menopause* 2023;30:-9. doi: 10.1097/GME.0000000000002243 pmid: 37643393
- 4 Cho L, Kaunitz AM, Faubion SS, et al. ACC CVD in Women Committee. Rethinking menopausal hormone therapy: for whom, what, when, and how long? *Circulation* 2023;147:-610. doi: 10.1161/CIRCULATIONAHA.122.061559 pmid: 36780393
- 5 Koysombat K, Mukherjee A, Nyunt S, et al. Factors affecting shared decision-making concerning menopausal hormone therapy. *Ann N Y Acad Sci* 2024;1538:-44. doi: 10.1111/nyas.15185 pmid: 39014999
- 6 Manulife. Women's health report. <https://www.manulife.ca/business/news/group-benefits-news/womens-health.html>
- 7 Sundell M, Brynhildsen J, Spetz Holm AC, Fredrikson M, Hoffmann M. Trends in the incidence, prevalence and sales volume of menopausal hormone therapy in Sweden from 2000 to 2021. *Maturitas* 2023;175:107787. doi: 10.1016/j.maturitas.2023.107787 pmid: 37354643
- 8 Andrews R, Lacey A, Bache K, Kidd EJ. Hormone replacement therapy uptake and discontinuation trends from 1996-2023: An observational study of the Welsh population. *BJOG* 2025. doi: 10.1111/1471-0528.18220 pmid: 40384462
- 9 Mansour D, Barber K, Chalk G, et al. The evolving perspective of menopause management in the United Kingdom. *Womens Health (Lond)* 2024;20:17455057241288641. doi: 10.1177/17455057241288641 pmid: 39378060
- 10 Vollrath S, Theis S, Kolokythas A, et al. Self-management eHealth solutions for menopause - a systematic scoping review. *Climacteric* 2024;27:-68. doi: 10.1080/13697137.2024.2334035 pmid: 38685754
- 11 Osborne AK, Sillence E. Accessing information on menopause transition and the role of digital health technologies: A narrative review. *Women Health* 2025;65:-21. doi: 10.1080/03630242.2025.2523258 pmid: 40568889
- 12 Hill A. The 'huge disadvantage' women behind femtech phenomenon face. *The Guardian* 2024 Oct 8. <https://www.theguardian.com/society/2024/oct/08/the-huge-disadvantage-women-behind-femtech-phenomenon-face>
- 13 Precision Analytical Inc. DUTCH Test. <https://dutchtest.com>
- 14 Yuksel N, Treseng L, Malik B, Ogbogu U. Promotion and marketing of bioidentical hormone therapy on the internet: a content analysis of websites. *Menopause* 2017;24:-35. doi: 10.1097/GME.0000000000000901 pmid: 28609391
- 15 Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. *Menopause* 2015;22:-36. doi: 10.1097/GME.0000000000000420 pmid: 25692877
- 16 American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy: ACOG Clinical Consensus No. 6. *Obstet Gynecol* 2023;142:-73. doi: 10.1097/AOG.0000000000005395 pmid: 37856860
- 17 Hamoda H, Moger S, Morris E, et al. Menopause practice standards. *Post Reprod Health* 2022;28:-32. doi: 10.1177/2053369122110001 pmid: 35924760
- 18 American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstet Gynecol* 2014;123:-16. doi: 10.1097/01.AOG.0000441353.20693.78 pmid: 24463691
- 19 "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause* 2022;29:-94. doi: 10.1097/GME.0000000000002028 pmid: 35797481
- 20 National Institute for Health and Care Excellence (NICE). Menopause: Identification and Management. NICE guideline [NG23]. <https://www.nice.org.uk/guidance/ng23>.
- 21 Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2015;100:-4011. doi: 10.1210/jc.2015-2236 pmid: 26444994
- 22 Gunter J. Addressing the challenges of online misinformation and unregulated products in the clinical management of menopause. *Obstet Gynecol* 2025;146:-94. doi: 10.1097/AOG.0000000000005989 pmid: 40570352
- 23 Greene DN, Ahmed SB, Daccarett S, et al. A comprehensive review of estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone in the context of laboratory medicine to support women's health. *Clin Chem* 2025;71:-57. doi: 10.1093/clinchem/hvae039 pmid: 40247783
- 24 British Menopause Society. Progesterone and endometrial protection. <https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progesterone-and-endometrial-protection-APR2023-A.pdf>
- 25 Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials. *JAMA* 2013;310:-68. doi: 10.1001/jama.2013.278040
- 26 British Menopause Society. Measurement of serum estradiol in the menopause transition. BMS Tools for Clinicians. <https://thebms.org.uk/wp-content/uploads/2025/07/24-NEW-BMS-Toolsfor-Clinicians-Measurement-of-serum-estradiol-JULY2025-B.pdf>